Risperidone
- Generic Name
- Risperidone
- Brand Names
- Perseris, Risperdal, Rykindo, Uzedy, Okedi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 106266-06-2
- Unique Ingredient Identifier
- L6UH7ZF8HC
- Background
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...
- Indication
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...
- Associated Conditions
- Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
- Associated Therapies
- -
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2020-07-16
- Target Recruit Count
- 44
- Registration Number
- NCT03568500
- Locations
- 🇬🇧
Clinical Trial Site, Southampton, United Kingdom
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Synergy East, Lemon Grove, California, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States
Long-term Antipsychotic Pediatric Safety Trial
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Duke University
- Target Recruit Count
- 509
- Registration Number
- NCT03522168
- Locations
- 🇺🇸
UCLA Semel Institute, Los Angeles, California, United States
🇺🇸Beacon Medical Group, South Bend, Indiana, United States
🇺🇸Carolina Partners in Mental HealthCare, PLLC, Raleigh, North Carolina, United States
Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 1260
- Registration Number
- NCT03510325
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 26
- Registration Number
- NCT03323437
- Locations
- 🇺🇸
New York State Psychiatric Institute & Columbia University, New York, New York, United States
A Research in Pharmacogenomics and Accurate Medication of Risperidone
- Conditions
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Cui Yimin
- Target Recruit Count
- 800
- Registration Number
- NCT03302364
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 119
- Registration Number
- NCT03230864
- Locations
- 🇧🇬
DCC St. Vrach and St.St. Kuzma and Damian, Sofia, Bulgaria
🇧🇬MHC - Sofia, Sofia, Bulgaria
🇧🇬UMHAT, Pleven, Bulgaria
A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Peking University
- Target Recruit Count
- 300
- Registration Number
- NCT03148509
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up
- Conditions
- Interventions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Fundación Marques de Valdecilla
- Target Recruit Count
- 200
- Registration Number
- NCT03090503
- Locations
- 🇪🇸
University Hospital Marques de Valdecilla, Santander, Cantabria, Spain
Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2019-05-03
- Target Recruit Count
- 120
- Registration Number
- NCT03075657
- Locations
- 🇮🇳
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.